Hao K, Paik AJ, Han LH, Makary MS. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J Radiol 2024; 16(10): 512-527 [PMID: 39494134 DOI: 10.4329/wjr.v16.i10.512]
Corresponding Author of This Article
Mina S Makary, MD, Associate Professor, Attending Doctor, Director, Department of Radiology, The Ohio State University Medical Center, 395 West 12th Avenue, Columbus, OH 43210, United States. mina.makary@osumc.edu
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Radiol. Oct 28, 2024; 16(10): 512-527 Published online Oct 28, 2024. doi: 10.4329/wjr.v16.i10.512
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma
Kelly Hao, Andrew J Paik, Lauren H Han, Mina S Makary
Kelly Hao, Andrew J Paik, Lauren H Han, College of Medicine, The Ohio State University, Columbus, OH 43210, United States
Mina S Makary, Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, United States
Author contributions: All authors contributed meaningfully to the preparation of the manuscript. Hao K and Makary MS conceptualized and designed the study; Hao K, Paik AJ, and Han LH conducted the literature review, did the analysis, drafted the original manuscript, and made critical revisions; Makary MS supervised the review, advised the review design, and critically revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mina S Makary, MD, Associate Professor, Attending Doctor, Director, Department of Radiology, The Ohio State University Medical Center, 395 West 12th Avenue, Columbus, OH 43210, United States. mina.makary@osumc.edu
Received: June 3, 2024 Revised: October 14, 2024 Accepted: October 21, 2024 Published online: October 28, 2024 Processing time: 147 Days and 4.9 Hours
Core Tip
Core Tip: This comprehensive review explores Yttrium-90 transarterial radioembolization (TARE) as an effective locoregional therapy for hepatocellular carcinoma across various stages. It compares TARE’s advantages over other locoregional treatments and systemic therapies, emphasizing its role in enhancing treatment efficacy and patient outcomes. The potential of TARE in combination with systemic and immunotherapies is highlighted, pointing towards a future of precision medicine through personalized treatments. This comprehensive review aims to elucidate TARE’s efficacy, safety, and evolving role in hepatocellular carcinoma management. By addressing emerging findings and new methodologies, we aim to advance the understanding and application of this promising technique in interventional radiology.
